|Articles|August 1, 2003

Multiple-dose regimen safe for neovascular AMD

Fort Lauderdale, FL-In a phase I, multicenter, randomized trial, the anti-VEGF antibody fragment rhuFab V2 was shown to be safe and well-tolerated in eyes with neovascular age-related macular degeneration (AMD), according to Philip J. Rosenfeld, MD, PhD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME

Video

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

Multiple-dose regimen safe for neovascular AMD

Related Content

Frantz EyeCare LAL outcomes exceed national benchmarks in single-center cataract data

Emerging dry eye therapies and co-managing MGD: Ping Moore, OD

Why aren’t there enough ophthalmologists?

Personalizing dry eye treatment by addressing disease at its source

Root cause–based dry eye classification and the shift toward precision medicine

Latest CME

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

EyeCon 2026

Join Us at The Ophthalmology Meeting This October in New Orleans

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

(COPE) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights

(CME) The Truth About Presbyopia Drops: Evidence-Based Cases and Myth-Busting Insights